Waters Bullish on Proteomics, Predicts Big Pharma Will Soon Come Around | GenomeWeb

SAN FRANCISCO, Jan. 8 - Waters has its eye on proteomics and is prepared to move forward with investments and acquisitions in the field, CEO Douglas Berthiaume said on Tuesday.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.